Mu Opioids Induce Biased Signaling at the Full-Length Seven Transmembrane C-Terminal Splice Variants of the mu Opioid

Ankita Narayan1, Amanda Hunkele1, Jin Xu1

  • 1Department of Neurology and the Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA.

Insights

Mu opioid receptor (MOR) C-terminal variants exhibit distinct biased signaling profiles, influencing G protein and β-arrestin2 recruitment differently. This finding offers new insights into opioid pharmacology and the development of safer analgesics.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Genetics

Background:

  • Biased signaling in mu opioid receptor (MOR-1) involves G protein and β-arrestin2 pathways, with potential links to therapeutic effects and side effects.
  • The mu opioid receptor gene (OPRM1) produces multiple full-length 7 transmembrane (7TM) splice variants with distinct C-terminal tails due to alternative splicing.
  • These C-terminal variants are increasingly recognized for their roles in opioid pharmacology, necessitating an investigation into their specific signaling biases.

Purpose of the Study:

  • To investigate how different C-terminal variants of MOR affect G protein coupling and β-arrestin2 recruitment upon mu agonist stimulation.
  • To determine the extent of signaling bias induced by various C-terminal variants.
  • To elucidate the impact of C-terminal variations on the differential signaling of MOR.

Main Methods:

  • Characterization of G protein activation by mu agonists across different MOR C-terminal variants.
  • Quantification of β-arrestin2 recruitment in response to mu agonists binding to various MOR variants.
  • Comparative analysis of signaling bias among distinct MOR C-terminal isoforms.

Main Results:

  • Mu agonists induced significant differences in G protein activation and β-arrestin2 recruitment among the studied C-terminal variants.
  • The MOR-1O variant (exon 7-associated) displayed a greater β-arrestin2 bias compared to the MOR-1 variant (exon 4-associated) for most mu agonists.
  • Evidence of biased signaling at multiple levels was observed across the different C-terminal variants.

Conclusions:

  • A single mu agonist can elicit differential signaling through multiple 7TM splice variants of the mu opioid receptor.
  • The C-terminal variants of MOR play a crucial role in determining the biased signaling profile.
  • These findings provide a novel perspective on biased signaling for OPRM1 and may be vital for understanding complex in vivo opioid actions.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.4K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.3K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
743
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
646
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
59.8K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.5K